Literature DB >> 11500492

Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site.

J Whittaker1, A V Groth, D C Mynarcik, L Pluzek, V L Gadsbøll, L J Whittaker.   

Abstract

The high resolution crystal structure of an N-terminal fragment of the IGF-I receptor, has been reported. While this fragment is itself devoid of ligand binding activity, mutational analysis has indicated that its N terminus (L1, amino acids 1-150) and the C terminus of its cysteine-rich domain (amino acids 190-300) contain ligand binding determinants. Mutational analysis also suggests that amino acids 692-702 from the C terminus of the alpha subunit are critical for ligand binding. A fusion protein, formed from these fragments, binds IGF-I with an affinity similar to that of the whole extracellular domain, suggesting that these are the minimal structural elements of the IGF-I binding site. To further characterize the binding site, we have performed structure directed and alanine-scanning mutagenesis of L1, the cysteine-rich domain and amino acids 692-702. Alanine mutants of residues in these regions were transiently expressed as secreted recombinant receptors and their affinity was determined. In L1 alanine mutants of Asp(8), Asn(11), Tyr(28), His(30), Leu(33), Leu(56), Phe(58), Arg(59), and Trp(79) produced a 2- to 10-fold decrease in affinity and alanine mutation of Phe(90) resulted in a 23-fold decrease in affinity. In the cysteine-rich domain, mutation of Arg(240), Phe(241), Glu(242), and Phe(251) produced a 2- to 10-fold decrease in affinity. In the region between amino acids 692 and 702, alanine mutation of Phe(701) produced a receptor devoid of binding activity and alanine mutations of Phe(693), Glu(693), Asn(694), Leu(696), His(697), Asn(698), and Ile(700) exhibited decreases in affinity ranging from 10- to 30-fold. With the exception of Trp(79), the disruptive mutants in L1 form a discrete epitope on the surface of the receptor. Those in the cysteine-rich domain essential for intact affinity also form a discrete epitope together with Trp(79).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500492     DOI: 10.1074/jbc.M102863200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Structural determinants of the insulin receptor-related receptor activation by alkali.

Authors:  Igor E Deyev; Alla V Mitrofanova; Egor S Zhevlenev; Nikita Radionov; Anastasiya A Berchatova; Nadezhda V Popova; Oxana V Serova; Alexander G Petrenko
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

2.  The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.

Authors:  Meizhen Lou; Thomas P J Garrett; Neil M McKern; Peter A Hoyne; V Chandana Epa; John D Bentley; George O Lovrecz; Leah J Cosgrove; Maurice J Frenkel; Colin W Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

Review 3.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

4.  IGF1R variants associated with isolated single suture craniosynostosis.

Authors:  Michael L Cunningham; Jeremy A Horst; Mark J Rieder; Anne V Hing; Ian B Stanaway; Sarah S Park; Ram Samudrala; Matthew L Speltz
Journal:  Am J Med Genet A       Date:  2011-01       Impact factor: 2.802

Review 5.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  Precise mapping of an IGF-I-binding site on the IGF-1R.

Authors:  Mehrnaz Keyhanfar; Grant W Booker; Jonathan Whittaker; John C Wallace; Briony E Forbes
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

7.  Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.

Authors:  Ming Zhao; Zhu-li Wan; Linda Whittaker; Bin Xu; Nelson B Phillips; Panayotis G Katsoyannis; Faramarz Ismail-Beigi; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

8.  Contribution of residue B5 to the folding and function of insulin and IGF-I: constraints and fine-tuning in the evolution of a protein family.

Authors:  Youhei Sohma; Qing-xin Hua; Ming Liu; Nelson B Phillips; Shi-Quan Hu; Jonathan Whittaker; Linda J Whittaker; Aubree Ng; Charles T Roberts; Peter Arvan; Stephen B H Kent; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-12-03       Impact factor: 5.157

Review 9.  The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.

Authors:  V Kate Gatenby; Helen Imrie; Mark Kearney
Journal:  Pflugers Arch       Date:  2013-01-22       Impact factor: 3.657

10.  Structural basis of the aberrant receptor binding properties of hagfish and lamprey insulins.

Authors:  Waseem Sajid; Patricia A Holst; Vladislav V Kiselyov; Asser S Andersen; J Michael Conlon; Claus Kristensen; Thomas Kjeldsen; Jonathan Whittaker; Shu J Chan; Pierre De Meyts
Journal:  Biochemistry       Date:  2009-12-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.